In the bustling pharmacies of Peshawar’s Namak Mandi, the transaction is no longer a simple exchange of currency for health. It has become a negotiation of survival. Since early 2026, the cost of life-saving insulin delivery devices has jumped from PKR 2,200 to a staggering PKR 4,720, while the price of basic thyroid medication has surged by over 240 percent. For the 40 million residents of Khyber-Pakhtunkhwa (KP), these numbers are not just inflationary statistics; they represent a systemic failure of the pharmaceutical supply chain that is forcing families to choose between food and the medicine that keeps them alive.
The crisis is rooted in a toxic convergence of federal policy shifts, provincial funding shortfalls, and a controversial price deregulation strategy that has backfired on the most vulnerable. While the Drug Regulatory Authority of Pakistan (DRAP) maintains that "essential medicines" remain price-controlled, a massive loophole has emerged. By deregulating prices for products not listed on the National Essential Medicines List (NEML), the government effectively signaled to manufacturers that they could recoup their losses on the backs of chronic disease patients. Recently making news lately: The Great Protein Deception Why Plant Based Propaganda is Making Americans Sicker.
The Deregulation Trap
In late 2024, the federal government moved toward a "market-driven" pricing model for non-essential drugs. The logic was standard economic theory: allow prices to rise, and manufacturers will have the incentive to maintain supply, thereby ending the chronic shortages that plagued the country throughout 2023. In reality, this has created a two-tier healthcare system.
Pharmaceutical companies, squeezed by the rising cost of importing Active Pharmaceutical Ingredients (APIs)—70 percent of which originate in China and India—have shifted their production focus. When a manufacturer can increase the price of a digestive aid or a vitamin supplement by 20 percent without regulatory interference, they naturally prioritize those over the low-margin, price-capped essentials. This "margin migration" has led to a paradoxical situation where shelves are stocked with expensive supplements while basic antibiotics and blood pressure medications vanish. More details regarding the matter are explored by Mayo Clinic.
The impact in KP is particularly acute due to the province's geography and its reliance on the Sehat Card program. The program, once a flagship for universal health coverage, is now buckling. With the federal government ruling out further funding for provincial health insurance schemes in January 2026, KP has been left to foot a multi-billion rupee bill while facing a PKR 76 billion shortfall in federal revenue transfers.
The Human Cost of Policy Gaps
Consider the case of a diabetic patient in the merged districts of the former FATA. Under the previous subsidy model, insulin was largely accessible. Today, that same patient faces a choice. The HumaPen Ergo II, a standard delivery device, now costs more than double what it did last year. When the price of an essential tool jumps 114 percent in a matter of months, "access" becomes a purely theoretical concept.
Medical professionals in Peshawar report a worrying trend: treatment fragmentation. Patients are no longer following their prescribed regimens. Instead of taking a daily pill, they take one every three days. Instead of full insulin doses, they "micro-dose" to stretch their supply. This isn't just a financial problem; it is a ticking time bomb for the public health system. Sub-therapeutic dosing leads to complications—kidney failure, strokes, and blindness—that will eventually cost the provincial government far more in emergency care than a subsidy would have cost today.
The Black Market and Substandard Alternatives
Where the formal market fails, the shadow market thrives. The price hikes in KP have triggered a surge in the availability of "smuggled" drugs from across the Afghan border. While these medications are often 30 to 40 percent cheaper, they lack the cold-chain integrity required for products like insulin.
Quality compromise is the silent killer in this crisis. Provincial drug inspectors are currently overwhelmed, attempting to monitor thousands of small-scale pharmacies with a budget that has been slashed by 15 percent in real terms due to inflation. When a patient buys a vial of insulin for half the market price at a back-alley clinic, they aren't just buying medicine; they are gambling with their life.
The Federal-Provincial Fiscal Standoff
The "why" behind the crisis eventually leads to a spreadsheet in Islamabad. The federal government insists that under the 18th Amendment, health is a devolved subject. They argue that provinces must generate their own revenue to fund these schemes. KP’s finance department counter-argues that the federal government is withholding the province’s rightful share of the National Finance Commission (NFC) award and Net Hydel Profits.
This fiscal tug-of-war has paralyzed the provincial government’s ability to intervene. In March 2026, KP officials warned that the funding gap is so severe it could derail the delivery of even basic services in the merged districts. When the state stops paying its bills, the pharmaceutical distributors are the first to stop deliveries. In remote areas of Chitral and Kohistan, pharmacies are reporting that wholesalers are demanding "upfront cash only," a demand that small-town chemists simply cannot meet.
The Manufacturers' Defense
The Pakistan Pharmaceutical Manufacturers Association (PPMA) argues that they are not the villains of this story. They point to a 20 percent increase in fuel prices and a volatile rupee that makes every gram of imported raw material a financial risk. From their perspective, if prices don't rise, the factories close. They argue that 85 percent of medicines are manufactured locally, but that "local" label is deceptive—the assembly is local, but the ingredients are global.
The industry is currently facing a "pill penalty." Small-molecule drugs and biologics are subject to complex negotiation windows that manufacturers claim stifle investment. If a company knows its revenue will be capped by DRAP while its costs are dictated by the global oil market and shipping lanes, it will eventually stop producing the product altogether. This is why we see "artificial shortages"—the medicine exists in the warehouse, but it is not "economically viable" to put it on a truck to Peshawar.
The Path to Stabilisation
Fixing the healthcare crisis in KP requires moving beyond the "emergency decree" mindset. A three-pronged approach is necessary to prevent a total collapse:
- Revising the NEML: The National Essential Medicines List must be updated to include modern delivery devices like insulin pens. Labeling the medicine as "essential" but the device as "luxury" is a bureaucratic absurdity that kills patients.
- Provincial Procurement Hubs: KP needs to bypass the traditional retail supply chain for chronic disease medications. By establishing provincial bulk-buying hubs, the government can leverage its scale to negotiate lower prices directly with manufacturers, bypassing the retail markups that are currently gouging the public.
- Contributory Health Insurance: The era of "free" universal health coverage is likely over given Pakistan’s current fiscal reality. Transitioning the Sehat Card to a contributory model—where those who can afford it pay a small premium—could stabilize the fund and ensure that subsidies are reserved for the 32.5 percent of the population living below the poverty line.
The current trajectory is unsustainable. If the price of survival continues to climb at triple-digit rates, the "healthcare crisis" will transform into a broader social upheaval. In the high-stakes world of pharmaceutical economics, the margin for error has disappeared. The government must decide whether it wants to protect a deregulated market or a living population.
Demand immediate transparency from DRAP on the "price-notified" list to prevent retailers from overcharging for capped goods.
